Questcor's (QCOR -7.3%) early drubbing was apparently due to a mistaken headline stating that a...

|By:, SA News Editor

Questcor's (QCOR -7.3%) early drubbing was apparently due to a mistaken headline stating that a synthetic version of Acthar had been approved by the FDA, rather than the Orphan Drug Designation it had actually been given, according to a Seeking Alpha contributor. The errant headline has since been pulled and refiled to reflect the correction, but the hangover in the shares continues in mid-day trading nontheless.